Related Experiment Video
Updated: Feb 24, 2026

10:28
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
16.4K
Nonmotor Fluctuations in Parkinson's Disease
Christiana Franke1, Alexander Storch2
1Charité-Universitätsmedizin Berlin, Berlin, Germany.
International Review of Neurobiology
|August 15, 2017
Summary
Advanced Parkinson's disease (PD) patients experience fluctuating nonmotor symptoms (NMF), similar to motor fluctuations. Continuous dopaminergic stimulation may offer a therapeutic strategy for NMF, warranting further clinical trials.
Area of Science:
- Neurology
- Movement Disorders
- Parkinson's Disease Research
Background:
- Advanced Parkinson's disease (PD) presents motor complications like fluctuations and dyskinesias from levodopa.
- Nonmotor symptoms (NMS), including neuropsychiatric, autonomic, and pain symptoms, also exhibit fluctuations (NMF) in PD patients with motor fluctuations.
Purpose of the Study:
- To highlight the clinical significance of nonmotor fluctuations (NMF) in advanced Parkinson's disease.
- To emphasize the lack of consideration and therapeutic studies for NMF in routine PD care.
- To propose potential therapeutic strategies for NMF based on their connection to motor fluctuations.
Main Methods:
- Review of recent clinical research on nonmotor fluctuations in Parkinson's disease.
- Analysis of the relationship between motor fluctuations and nonmotor symptoms.
- Exploration of potential therapeutic avenues based on existing knowledge of motor complication management.
Main Results:
- Growing evidence indicates that nonmotor symptoms fluctuate in PD patients experiencing motor fluctuations.
- Nonmotor fluctuations (NMF) are currently under-recognized and undertreated in advanced PD.
- The pathophysiology of NMF remains largely unknown, hindering the development of targeted therapies.
Conclusions:
- Nonmotor fluctuations (NMF) are a significant, yet overlooked, aspect of advanced Parkinson's disease.
- The close link between NMF and motor fluctuations suggests continuous dopaminergic stimulation as a potential therapeutic approach.
- Urgent need for controlled clinical trials specifically investigating NMF and their treatment is emphasized.
Related Concept Videos
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Neural Regulation
43.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.6K

